Initiation of dosing in our Phase 1b clinical trial represents an important step in the clinical development of GT-02287 and in Gain’s mission to deliver a disease-modifying therapy to people with ...

More advanced methods may enable better modelling Parkinson’s disease is a considerable health problem owing to its high and rising global prevalence, its progressively degenerative nature, and its ...

By 2050, there will be 25.2 million people living with Parkinson's disease worldwide (a 112% increase from 2021), largely due ...

Parkinson's disease cases are projected to double globally by 2050, reaching 25 million individuals, according to a recent ...

The Michael J. Fox Foundation for Parkinson’s Research is supporting a study addressing mobility challenges in Parkinson’s ...

Interim Analysis Expected End of 2Q 2025 BETHESDA, MD / ACCESS Newswire / March 14, 2025 / Gain Therapeutics, Inc. (Nasdaq:GANX) ("Gain", or the "Company"), a clinical-stage biotechnology company lead ...

[11] Rizek P, An update on the diagnosis and treatment of Parkinson’s disease. 2016. [12] Heiss JD, et al. Trial of magnetic resonance-guided putaminal gene therapy for advanced Parkinson’s ...

By 2050, there will be 25.2 million people living with Parkinson’s disease worldwide (a 112% increase from 2021), largely due to population ageing, suggests a modelling study published by The ...

Parkinson’s disease is set to rise dramatically, with cases expected to more than double by 2050, largely due to an aging ...

Hospice use varies depending on whether a person has Parkinson’s disease, Lewy body dementia or Alzheimer’s disease and those with Parkinson’s may have more unmet needs, a new study finds.